prospective cohort

Related by string. * PROSPECTIVE . prospectives . pro spective . Prospective : Identify prospective partners . prospective buyer . prospective groom . prospective jurors . • Identify prospective / cohorts . Cohort . Cohorts . co horts . co hort : Swedish Mammography Cohort . dosing cohorts . dosing cohort . retrospective cohort study . retrospective cohort * Prospective Cohort Study *

Related by context. All words. (Click for frequent words.) 74 retrospective cohort study 72 randomized controlled trial 70 observational study 70 longitudinal study 69 retrospective cohort 69 multicenter study 68 longitudinal cohort study 68 randomized clinical 67 prospective observational 67 Swedish Mammography Cohort 67 Cohort Study 67 observational cohort study 67 substudy 67 randomized 66 Multi Ethnic Study 66 multicentre 65 retrospective observational study 65 Communities ARIC Study 64 Atherosclerosis MESA 64 randomized controlled 64 Framingham Offspring Study 64 Communities ARIC study 64 multicenter 64 Atherosclerosis Risk 64 randomized placebo controlled 64 placebo controlled 64 meta analysis 64 multicentre prospective 63 NHANES III 63 prospective observational cohort 63 randomized controlled trials 63 Wisconsin Sleep Cohort 63 nonrandomized 62 nulliparous women 62 multicentre study 62 trials RCTs 62 observational cohort 62 double blind placebo 62 Nutrition EPIC 62 Intervention Trial 62 Prospective Investigation 62 multiple logistic regression 62 randomized double 61 liver transplant recipients 61 n = 61 randomized trials 61 Prostate Lung Colorectal 61 dietary questionnaires 61 RE LY ® 61 prospective longitudinal 61 Framingham Offspring 61 multivariate logistic regression 61 observational studies 60 prospective randomized 60 subanalysis 60 Health Initiative Observational 60 blind randomized 60 INTERHEART study 60 epidemiologic studies 60 double blinded randomized 60 normotensive 60 CARDIA 60 logistic regression model 60 blind placebo controlled 60 multicenter randomized 60 Netherlands Cohort Study 60 randomized crossover 60 epidemiologic 60 multicentre randomized 59 prospective multicentre 59 postmenopausal women 59 placebo controlled clinical 59 NHANES 59 multicenter randomized controlled 59 blind randomized placebo 59 Longitudinal Study 59 CARDIA study 59 Randomized controlled 59 pharmacokinetics PK 59 cohort 59 multicenter prospective 59 DCCT 59 SORT OUT III 59 meta regression 59 placebo controlled Phase III 59 Millennium Cohort Study 59 undergoing coronary angiography 59 Health Initiative WHI 59 Multiethnic Study 58 subclinical hypothyroidism 58 prospective randomized controlled 58 Multiethnic Cohort Study 58 Birth Cohort 58 Young Adults CARDIA 58 Carotid Revascularization Endarterectomy vs. 58 Screening Trial 58 PLCO 58 randomized multicenter trial 58 logistic regression analysis 58 randomized multicenter 58 ExTRACT TIMI 58 nondiabetic 58 multicenter phase 58 MetS 58 NICE SUGAR 58 cardiovascular mortality 58 bivariate analyzes 58 randomized blinded 58 Alpha Tocopherol Beta Carotene 58 multivariate analysis 58 singleton pregnancies 57 conditional logistic regression 57 prospectively defined 57 Multicenter AIDS 57 dietary intakes 57 prospectively randomized 57 serum lipid levels 57 randomized controlled clinical 57 HYVET 57 randomized clinical trials 57 longitudinal studies 57 covariate 57 placebo controlled trials 57 gallstone disease 57 retrospectively analyzed 57 Multicenter 57 STRIDE PD 57 multicenter Phase II 57 Cholesterol Levels SPARCL 57 blind randomized controlled 57 atherothrombotic disease 57 logistic regression analyzes 57 prospective observational studies 57 Collaborative Perinatal Project 57 controlled multicenter 57 THIS STUDY 57 covariates 57 univariate 57 placebo controlled studies 57 HCV SPRINT 57 serum vitamin D 57 longitudinal observational study 57 HIV seronegative 57 multivariate analyzes 57 randomized Phase III 57 dietary patterns 57 Nutrition Examination Survey NHANES 57 blinded randomized controlled 57 MADIT CRT trial 56 multicenter randomized double 56 Prostate Cancer Prevention 56 symptomatic BPH 56 comorbidity 56 Avon Longitudinal Study 56 Univariate analysis 56 subgroup analyzes 56 multicentre randomized double 56 logistic regression models 56 controlled dose escalation 56 Professionals Follow 56 anthropometric measurements 56 Subgroup analyzes 56 Dietary Modification Trial 56 postintervention 56 GISSI HF 56 logistic regression 56 multivariate Cox 56 aged ≥ 56 multivariable analysis 56 nondiabetic patients 56 folate supplementation 56 sociodemographic characteristics 56 tertiles 56 Multivariate logistic regression 56 Study ARIC 56 prepubertal 56 HIV HCV coinfected 56 nonfatal MI 56 placebo controlled dose escalation 56 psychiatric morbidity 56 premenopausal women 56 histologically confirmed 56 Ovarian Cancer Screening 56 limiting generalizability 56 Cardiovascular Risk Factors 56 CVD mortality 56 BOLDER II 56 CC genotype 56 BMI waist circumference 56 randomized blinded placebo 56 CAMMS# 56 blinded randomized placebo controlled 56 Cohort 56 cerebral microbleeds 56 colorectal adenoma 56 atherogenic dyslipidemia 55 blinded randomized 55 PRECiSE 55 sociodemographic 55 Thrombolysis 55 serum estradiol 55 clinico pathological 55 dietary intake 55 RCTs 55 undergone radical prostatectomy 55 SYNTAX trial 55 NSTE ACS 55 nonpregnant women 55 randomized multicenter Phase III 55 multicentric 55 MADIT II 55 multivariable logistic regression 55 randomized controlled trials RCTs 55 treatment naive genotype 55 prospective randomized multicenter 55 HRQoL 55 multicenter multinational 55 STEP BD 55 prospective multicenter 55 highest tertile 55 XIENCE V demonstrated 55 UKPDS 55 vertebral fracture 55 depressive symptoms 55 socio demographic 55 single ascending dose 55 anovulatory infertility 55 dietary calcium intake 55 Osteoporotic Fractures 55 prospective nonrandomized 55 underwent CABG 55 placebo controlled Phase 55 antiretroviral naïve 55 T1DM 55 National Birth Cohort 55 hip BMD 55 urolithiasis 55 postmenopausal 55 Polyp Prevention Trial 55 prospective multicenter study 55 venous thromboembolic disease 55 RE LY trial 55 multicenter randomized clinical 55 Myocardial Infarction Study 55 blind placebo 55 Dialysis Outcomes 55 Normative Aging Study 55 statistically significant 55 myocardial infarctions MIs 55 adenotonsillectomy 55 REYATAZ ritonavir 55 Logistic regression 55 premenopausal 55 Baltimore Longitudinal Study 55 NSABP B 55 epidemiological 55 WHEL 55 placebo controlled randomized 54 REGARDS 54 double blinded placebo 54 Twin Registry 54 seroprevalence 54 placebo controlled clinical trials 54 carotid atherosclerosis 54 IPAH 54 beta carotene supplementation 54 ragweed allergic 54 multicenter trials 54 perinatal outcomes 54 diabetes mellitus DM 54 Cardiovascular Risk 54 Val HeFT 54 serum GGT 54 ECASS 54 randomized controlled clinical trials 54 BARI 2D 54 genomewide association study 54 Phase III randomized 54 NHANES #-# 54 serum uric acid 54 prospective randomized placebo 54 underwent radical prostatectomy 54 serum IGF 54 Cochrane Systematic Review 54 Kaplan Meier analysis 54 fasting insulin 54 NLSY 54 CHD mortality 54 dose dose escalation 54 Diabetes Interventions 54 EURIDIS 54 dyslipidaemia 54 Clinical Antipsychotic Trials 54 epidemiological studies 54 ELBW infants 54 Ovarian PLCO Cancer 54 thyrotropin levels 54 overnight polysomnography 54 Aggressive Reduction 54 NCT# ClinicalTrials.gov 54 HRQOL 54 treatment naïve genotype 54 colorectal neoplasia 54 Multivariate analyzes 54 polyarticular 54 WHIMS 54 prospectively evaluated 54 mammographic density 54 GISSI 54 colorectal cancer incidence 54 Digital Mammographic Imaging 54 metaanalysis 54 National Longitudinal Survey 54 VADT 54 BRFSS 54 INTERMAP 54 nondepressed 54 serum selenium 54 CALGB 54 macrovascular disease 54 generalizability 54 National Epidemiologic Survey 54 blinded placebo controlled 54 histologically proven 54 multicenter placebo controlled 54 unstable angina pectoris 54 Complications Trial 54 suicide attempters 54 HF ACTION 54 HIV uninfected 53 GH deficiency 53 NIDDM 53 Study AREDS 53 Edge STudy 53 landmark ATHENA 53 univariate analyzes 53 Multicentre 53 conducted retrospective cohort 53 underwent bariatric surgery 53 hsCRP levels 53 dose escalation study 53 BPS IC 53 ConclusionThis 53 ONTARGET 53 BMD measurements 53 Early Childhood Longitudinal Study 53 virological response 53 LUX Lung 53 Longitudinal 53 randomized Phase IIb 53 Meta analyzes 53 Rakai Uganda 53 RECORD1 53 Myocardial Infarction 53 postoperative AF 53 TMC# C# 53 hemodialysis patients 53 Observational Study 53 myocardial infarction MI 53 biochemical recurrence 53 pre menopausal 53 perinatal mortality 53 PLCO trial 53 Observational studies 53 multivariable analyzes 53 tertile 53 ANCOVA 53 FAME Study 53 CHAMPION PCI 53 Randomized Evaluation 53 #mg/day [001] 53 aneurysmal subarachnoid hemorrhage 53 Conclusions 53 estimated GFR 53 Acta Paediatrica 53 coronary revascularization 53 HCV RESPOND 2 53 symptomatic VTE 53 multicenter randomized placebo controlled 53 % CI #.#-#.# [006] 53 ascending dose 53 Baseline characteristics 53 neoadjuvant 53 Primary endpoints 53 psychiatric outpatients 53 METHODS 53 study 53 lipid lowering therapy 53 randomly assigned 53 NO# [002] 53 morphometric vertebral fractures 53 Poisson regression 53 preintervention 53 multicenter Phase III 53 Sorafenib HCC Assessment 53 BMI z 53 Clinical Outcomes Utilizing Revascularization 53 odds ratios ORs 53 LVSD 53 prospectively 53 genetic variants associated 53 cluster randomized controlled 53 Longitudinal studies 53 parous 53 anthropometric measures 53 index BMI 53 ascending doses 53 bivariate 53 CARE HF 53 Univariate 53 NHANES surveys 53 Arch Intern Med 53 NCCTG N# 53 REALITY Trial 53 ug dose 53 pharmacodynamic PD 53 pharmacokinetic PK 53 habitual snoring 53 adiponectin concentrations 53 HORIZONS AMI trial 53 micronutrient supplementation 53 hippocampal volume 53 NIH CPSI 53 GYTS 53 RE LY 53 SYNTAX 53 obese postmenopausal 52 colorectal adenomas 52 prostate cancer CaP 52 ACUITY trial 52 Randomized Study 52 dosing cohorts 52 ALLHAT 52 Nutrition Examination Surveys NHANES 52 fasting serum 52 DAS# CRP 52 Fragile Families 52 randomized controlled multicenter 52 relapsed MM 52 spontaneous preterm delivery 52 homocysteine concentrations 52 Multivariate analysis 52 seronegative 52 perimenopausal women 52 Interview Survey 52 singleton births 52 non fasting triglycerides 52 familial clustering 52 Children ALSPAC 52 paclitaxel eluting stents 52 Phase IIIb study 52 recurrent VTE 52 ALSPAC 52 HbA1c levels 52 Insulin Resistance Atherosclerosis 52 TG MV 52 NATRECOR ® 52 advanced neoplasia 52 sociodemographic factors 52 viral kinetic 52 INTERHEART 52 telomere lengths 52 nonvertebral fractures 52 genetic polymorphisms 52 genotyped 52 depressive symptomatology 52 clinicopathological 52 Sociodemographic 52 TAXUS ARRIVE 52 folate intake 52 lacunar 52 #mg QD [002] 52 SPIRIT III 52 J Clin Oncol 52 affective disorders 52 ABCSG 52 Lp PLA 2 52 sociodemographic variables 52 Logistic regression analysis 52 coronary heart 52 Epidemiological Study 52 potential confounders 52 authors conclude 52 prevalences 52 allele frequencies 52 Echocardiographic 52 CLBP 52 rosuvastatin 52 recurrent malignant glioma 52 Subgroup analysis 52 correlational 52 Stenting Trial CREST 52 statistically nonsignificant 52 Randomized Controlled Trial 52 microalbuminuria 52 Acute Decompensated Heart Failure 52 THIS STUDY analyzed 52 Acute Coronary Syndromes ACS 52 glycated hemoglobin HbA1c 52 plasma folate 52 Diabetologia 52 QoL 52 definite stent thrombosis 52 ATACAND 52 Comorbidity 52 resected pancreatic cancer 52 tumor histology 52 polysomnogram 52 stepwise logistic regression 52 Phase 1b trial 52 label multicenter 52 clinically localized prostate 52 AIR CF1 52 recurrent venous thromboembolism 52 genotype 52 adenoma recurrence 52 Determinants 52 iPrEx study 52 BRIM3 52 VLBW 52 recurrent UTI 52 chorioamnionitis 52 VLBW infants 52 virologic 52 abdominal ultrasounds 52 REYATAZ r arm 52 linear regression analyzes 52 XIENCE V Stent System 52 Acute Coronary Syndromes 52 Women Ischemia Syndrome 52 IMPROVE HF 52 interobserver 52 prepregnancy 52 IDDM 52 Replication NCS R 52 National Comorbidity Survey 52 URTI 52 breast carcinoma 52 clinicopathologic 52 Nationwide Inpatient Sample 52 Systolic Hypertension 52 Randomized Controlled Trials 52 CATIE AD 52 phase IIa 52 carotid stenosis 52 Histopathologic 52 composite endpoint 52 orofacial clefts 52 lignan intake 52 Chronic Heart Failure 52 multiple linear regression 52 HeFT 52 ovariectomized 52 macronutrient intake 52 echocardiographic parameters 52 bulimia nervosa 52 % CI #.#-#.# [008] 52 beta blocker therapy 52 antiretroviral naive 52 multivariable Cox 51 unfractionated heparin UFH 51 % CI #.#-#.# [003] 51 Nonalcoholic Fatty Liver Disease 51 NIHSS score 51 death reinfarction 51 nonfasting triglyceride levels 51 elective percutaneous coronary 51 carotid plaques 51 clinical trial 51 stage IIIb IV 51 hydroxyvitamin D levels 51 Screening Trial DMIST 51 ILLUSTRATE 51 adiposity 51 liver biopsies 51 random sample 51 Kruskal Wallis test 51 NYHA functional class 51 LV dysfunction 51 Prospective Cohort Study 51 prognostic significance 51 TAXUS IV 51 CYP#D# genotype 51 TAXUS VI 51 cryptogenic 51 BCIRG 51 T2DM 51 BJU International 51 β blockers 51 endometrial carcinoma 51 desvenlafaxine succinate 51 Interview Survey CHIS 51 STICH trial 51 phase Ib 51 safety tolerability pharmacokinetics 51 cardiovascular disease CVD 51 National Longitudinal Study 51 EORTC 51 salivary cortisol 51 Multiple logistic regression 51 patients undergoing percutaneous 51 chest radiographs 51 HRQL 51 hepatic resection 51 coinfected patients 51 macrovascular 51 Phase Ib clinical 51 conjugated equine estrogen 51 comorbid psychiatric disorders 51 ENGAGE AF TIMI 51 Evaluation WISE 51 blind multicenter 51 Sprague Dawley rats 51 PARTNER Trial 51 Scandinavian Simvastatin Survival 51 pharmacodynamic effects 51 EVEREST II 51 prospectively stratified 51 estimated glomerular filtration 51 multivariable adjusted 51 clinical pharmacology studies 51 androgen suppression 51 mg BID dose 51 subtrochanteric 51 metabolic syndrome MetS 51 Skin sterol 51 binary logistic regression 51 anthropometric 51 T2D 51 urodynamic 51 nonfasting triglycerides 51 Asymptomatic 51 TRITON TIMI 51 persistent pulmonary hypertension 51 SEER database 51 PROactive study 51 RIO Lipids 51 dose escalation clinical 51 PCI ExTRACT TIMI 51 multicenter clinical 51 intraobserver 51 Secondary efficacy endpoints 51 plasma selenium 51 non valvular atrial 51 femoral neck BMD 51 euthyroid 51 meta analyzes 51 AIM HIGH 51 plasma homocysteine levels 51 F FDG PET 51 elevated CRP 51 Main Outcome Measures 51 dose escalation Phase 51 univariate analysis 51 semistructured interviews 51 EQUATE OB 51 elevated LDL cholesterol 51 onset atrial fibrillation 51 Kaplan Meier curve 51 TAXUS ATLAS 51 undergone hysterectomies 51 riociguat 51 J Nutr 51 multivariate adjustment 51 Brief Psychiatric 51 NMIBC 51 spontaneous preterm birth 51 DMIST 51 Ischemic Heart Disease 51 Insulin sensitivity 51 familial aggregation 51 nadroparin 51 DAS# scores 51 Cohort Study MACS 51 RSD# oral 51 Health Examination Survey 51 seropositivity 51 Controlled Trial 51 sedentary postmenopausal 51 Buijsse 51 coronary calcification 51 confidence interval #.#-#.# 51 HCV infected 51 atherothrombosis 51 rs# [001] 51 HIV seroconversion 51 Myocardial Infarction TIMI 51 postoperative mortality 51 Slone Epidemiology Center 51 fasting triglyceride levels 51 elevated triglycerides 51 LEXIVA r 51 Regression analyzes 51 MEND CABG 51 Gynecologic Oncology Group 51 MMSE score 51 dysglycemia 51 acrylamide intake 51 virologic failure 51 underwent liver transplantation 51 AREDS 51 Prehypertension 51 unblinded 51 underwent surgical resection 51 undergoing coronary artery 51 patientswith 51 echocardiographic 51 magnesium intake 51 acute coronary syndrome 51 diabetes mellitus 51 phase IIb 51 OPT CHF 51 prospectively enrolled 50 Surveillance Epidemiology 50 generalized estimating 50 AIR2 Trial 50 Group RTOG 50 adverse perinatal 50 leiomyomas 50 NNRTI resistance 50 ezetimibe simvastatin 50 mean ± SEM 50 Patency 50 inverse association 50 posttreatment 50 actigraphy 50 autonomic dysfunction 50 cotinine levels 50 BRCA mutation carriers 50 Response Evaluation Criteria 50 cerebral infarction 50 Prospective Randomized 50 study1 50 ELCAP 50 BMI percentile 50 Systematic Review 50 Dietary intake 50 asthma exacerbation 50 HNSCC 50 prespecified secondary 50 NEVO RES 50 advanced adenoma 50 antibody titer 50 operable breast cancer 50 Randomized 50 randomly selected sample 50 serum concentrations 50 Phase Ia 50 Thromboembolism 50 COPERNICUS 50 singleton pregnancy 50 schizophrenia schizoaffective disorder 50 patients undergoing CABG 50 drank pomegranate juice 50 susceptibility loci 50 confounders 50 acetabular fracture 50 underwent resection 50 systolic blood pressure 50 CaPSURE 50 AVERROES 50 TOHP 50 SWOG 50 TAXUS V 50 pharmacokinetic pharmacodynamic 50 atazanavir ritonavir 50 residual confounding 50 sonographic findings 50 tibolone 50 esophageal squamous cell carcinoma 50 candesartan 50 dose cohort 50 serum samples 50 multicenter Phase 50 ICSI cycles 50 pharmacodynamics 50 metabolic parameters 50 socioeconomic gradient 50 Phase 2b study 50 subscale scores 50 REACH Registry 50 Nord Trøndelag Health 50 highest quintile 50 comorbid depression 50 male Wistar rats 50 ERSPC 50 Intervention Effectiveness 50 choline intake 50 SPARCL 50 Acute Coronary Syndrome 50 CIMZIA TM certolizumab pegol 50 adenocarcinoma histology 50 oral glucose tolerance 50 randomized Phase 2b 50 onset diabetes mellitus 50 macroalbuminuria 50 HER2 expression 50 APTIVUS r 50 Histologic 50 pegylated interferon alfa 2b 50 AMOR IPAT 50 LNG IUS 50 dose escalation phase 50 HPTN 50 oral rivaroxaban 50 BR.# 50 fasting glucose levels 50 acute coronary syndromes ACS 50 safety tolerability pharmacokinetic 50 congenital toxoplasmosis 50 posttransplant 50 randomisation 50 Percutaneous Coronary Intervention 50 cardioembolic stroke 50 atopic sensitization 50 Canadian Multicentre Osteoporosis 50 doxorubicin docetaxel 50 LUTS 50 hypercholesterolaemia 50 subclinical atherosclerosis 50 RRMS patients 50 HRCT 50 underwent percutaneous coronary 50 CAVEATS 50 journal Ophthalmology 50 PREVENT IV 50 MACCE 50 flow mediated dilation 50 prespecified 50 PON1 activity 50 coronary artery calcification 50 gestational hypertension 50 serum lipids 50 logistic regressions 50 AIR CF2 50 Memory Study WHIMS 50 Hp2 2 50 biochemical relapse 50 Antiviral Therapy 50 ENDEAVOR IV 50 proband 50 hyperintense lesions 50 dose escalation trial 50 Ambulatory Blood Pressure 50 nonsignificant 50 Main Outcome Measure 50 nonpsychotic 50 elevated ALT 50 SWiTCH 50 statistically significant correlation 50 APPRAISE 50 postoperative atrial fibrillation 50 thromboembolic 50 cilostazol 50 masked placebo controlled 50 CHD CVD 50 nondemented 50 genotypic resistance 50 Phase 2a trial 50 adnexal mass 50 Postoperative 50 genotypic 50 Kaplan Meier estimate 50 attain statistical significance 50 menarche 50 prognostic variables 50 serum markers 50 weekly subcutaneous injections 50 safety tolerability 50 familial AF 50 Prospective Randomized Trial 50 2D 4D ratio 50 relapsing remitting MS RRMS 50 ischemic cardiomyopathy 50 GPNMB expression 50 Radiation Therapy Oncology 50 NHAMCS 50 eptifibatide 50 body fatness 50 attending antenatal clinics 50 Ann Intern Med 50 MDRD 50 confirmatory clinical 50 polytherapy 50 rs# [004] 50 syncopal 50 nutrient intakes 50 Nutritional Examination Survey 50 cardiometabolic risk 50 etiologic 50 Female Sexual Function 50 label dose escalation 50 skin sterol 50 Phase 1a clinical 50 folate vitamin B 50 primary hypercholesterolemia 50 Related Conditions NESARC 50 ipsilateral stroke 50 neurocognitive impairment 50 abnormal lipid 50 histologic subtype 50 Intervention Effectiveness CATIE 50 FACIT 50 eplerenone 50 Depressive Symptoms 50 lowest tertile 50 ENDEAVOR clinical 50 antioxidant supplementation 50 reach statistical significance 50 mg administered orally 50 genomewide 50 Phase IIIb 50 coinfection 50 nonobese 50 microbleeds 50 socioeconomic status SES 50 Multiple linear regression 50 adjuvant radiotherapy 50 hemoglobin A1c HbA1c 50 lipid levels 50 Body Composition Study 50 hypercholesterolemic 50 proportional hazards 50 Intervention Trial GAIT 50 osteopenic 50 serum creatinine levels 50 heterozygous familial 50 antihypertensive therapy 50 #:#-# [029] 50 overt hypothyroidism 50 antidiabetic medication 50 International Verapamil SR 50 irbesartan 50 rFVIIa 50 psychiatric comorbidities 50 serum leptin 50 prospective multicenter randomized 50 Lipid Lowering Treatment 49 tirofiban 49 microalbumin 49 comorbidities 49 hyperlipidemic 49 CYPHER R stent 49 Pharmacokinetic 49 Cancer Prevention ATBC 49 neoadjuvant treatment 49 comorbid illnesses 49 glycated hemoglobin levels 49 Sequenced Treatment Alternatives 49 neonatal morbidity 49 prostate cancer PCa 49 ToGA 49 intracerebral hemorrhage ICH 49 Karolinska Institutet Stockholm Sweden 49 angiographically 49 hypocaloric diet 49 Infarct 49 eGFR 49 daily subcutaneous injections 49 papillary renal cell carcinoma 49 postmenopausal hormone therapy 49 PSA nadir 49 alexithymia 49 Nutrition Examination 49 Bonferroni correction 49 hepatectomy 49 thyroid hormone levels 49 nomogram 49 cryptorchidism 49 semiquantitative 49 null responder HCV 49 APOE genotype 49 Cardiovascular Outcomes 49 EINSTEIN DVT 49 Endeavor Resolute DES 49 calcium supplementation 49 WHI 49 interpersonal psychotherapy 49 % CI #.#-#.# [002] 49 modifiable risk 49 Cytogenetic 49 SEER registry 49 Multicenter Study 49 statistically significant differences 49 post hoc 49 TEAEs 49 Fibromyalgia Impact Questionnaire 49 polycystic ovary syndrome PCOS 49 Heart Failure Trial 49 insulin detemir 49 Acute Myocardial Infarction 49 Kaplan Meier curves 49 antiretroviral regimen 49 IL#B 49 periprocedural 49 SEER registries 49 immunohistochemical staining 49 factorial design 49 fasting glucose

Back to home page